Washington Oregon Biotech Networks’ Post

 Major Partnerships in AI-focused biotech 🔬 Absci and AstraZeneca: A $247 million deal was announced in December 2023 to develop AI-designed anticancer antibodies. 🔬 BigHat Biosciences and AbbVie: A collaboration worth over $200 million to leverage AI for antibody development. 🔬 BigHat Biosciences and Almirall: A $610 million deal to create AI-designed therapeutics for dermatological diseases. 🔬 Sanofi and BioMap: A partnership potentially worth more than $1 billion to develop AI models for biological design. 🔬 Xaira Therapeutics, Co-founded by David Baker, is an AI-focused biotech that launched with over $1 billion in funding. It aims to use generative AI tools like diffusion models to design next-generation biologics. 🤝 These partnerships and innovations are not just significant; they are game-changers. They underscore the growing impact of AI in biotech, paving the way for faster and more efficient development of therapeutic antibodies. The integration of AI and biologics expertise is poised to revolutionize the industry, offering new hope for the treatment of various diseases. #artificalintelligence

𝐂𝐃𝐌𝐎 𝐌𝐚𝐫𝐤𝐞𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 🤳 🚀AGC Biologics & NEC Bio Therapeutics GmbH Partner to Advance Production of NECVAX-NEO1 Cancer Vaccine. This orally administered vaccine targets patient-specific tumor neoantigens using a bacteria-based DNA platform. It seeks to provide a personalized approach to cancer treatment by leveraging AI and machine learning technologies. 🏭Lonza Expands Bend Facility to Include Clinical Bottling and Labeling Services. This facility now supports more than 80 programs, with a focus on bioavailability enhancement and inhaled delivery. The integration of these new capabilities is anticipated to expedite the delivery of products to clinical trial centers, providing customers with increased speed and efficiency. 📈Phosphorex , a CDMO focused on drug delivery solutions, announced today that NOF CORPORATION has made a strategic investment in the company. Supported by Ampersand Capital Partners, this investment represents a significant milestone in Phosphorex’s growth strategy. 🎯👨💼QHP Capital has announced the appointment of Owen Murray as the new Chief Executive Officer for the recently combined entities of Bend Bioscience, CoreRx, and Societal. 🌐Singota Solutions expands its European operations by opening a new -40C and -20C storage facility near Milan, Italy. This expansion supports their logistics and 3PL solutions aimed at biologic products. 💉Abzena and Angiex Inc. Collaborate as AGX101 Enters Phase 1 Clinical Trials. AGX101 stands out for its dual-target approach, aiming to destroy tumor blood vessels, eliminate metastatic cells, and activate the immune system. Abzena played a key role in its development, handling everything from linker-payload design and bioconjugation to process development and cGMP manufacturing. Apsida Life Science #CDMO #news

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

Antibody Drug Conjugates (#ADCs) Keep Growing! Tubulis GmbH, a German ADC #biotech #startup, raises €128 million ($138.8 million) Series B2 financing to accelerate the clinical development of solid tumour-focused ADC pipeline. The financing round is co-led by EQT Life Sciences and Nextech Invest, with participation from current and new leading global biotechnology investors. According to MarketsandMarkets™’s report, the global ADCs market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, with a CAGR of 15.2% from 2023 to 2028. Other leading players in the global ADCs market include: - AbbVie/ ImmunoGen, Inc. - Adcendo - Adcentrx Therapeutics - Alentis Therapeutics - AstraZeneca/ Daiichi Sankyo, Inc. - BioNTech SE/ Duality Biologics - Bristol Myers Squibb - GSK - Innovent Biologics - Pfizer/ Seagen

Have you ever heard of covalent biologics? 🔗 The budding field of covalent biologics has made headway recently, as Enlaza Therapeutics has bagged $100 million in funding to move its pipeline to the clinic. 🏥 These drugs are meant to lock onto a target protein and form a lasting bond with it. This way cancer cells and inflammatory cells in autoimmune diseases can be targeted. 🎯 Labiotech spoke to Sergio Duron, CEO of preclinical company Enlaza, the only biotech involved in the space. Read our latest article to find out more about this new class of drugs! 👇 https://lnkd.in/dx7v5ZNF #covalentbiologics #biotech #healthcareinnovation #cancertherapy #autoimmunediseases #biotechfunding #pharmaceuticals #drugdevelopment #medicalresearch

$100 million to develop covalent biologics for oncology ! Enlaza Therapeutics just secured $100 million in Series A funding, led by J.P. Morgan Asset Management’s Private Capital division, to advance its covalent biologic platform for novel protein drugs, particularly in oncology. ⚗️Safer and more tolerable tumor penetration : Enlaza's War-LockTM technology creates biologic drugs that bind irreversibly to disease targets, enhancing efficacy and safety. By promoting covalency, it improves therapeutic performance, reduces systemic exposure, and allows sustained biologic effects with minimal dosing. Using proprietary amino acids, Enlaza engineers precise biological medicines with enhanced properties, offering a versatile solution across different protein-drug formats. 💊Investors : J.P. Morgan led the funding round, joined by existing investors like Frazier Life Sciences and new ones including Amgen and Regeneron's investment arms.

Biopharma Funding Activity May 20th-24th ‘24 2 newly launched companies and more funding events… Get these weekly → https://lnkd.in/gDdkUYb3 – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – AltruBio Inc. 💸  Received an oversubscribed Series B financing of up to $225M led by BVF Partners LP, and other investors to support ongoing and planned Phase 2a and 2b clinical trials of immune checkpoint enhancer, ALTB-268, in ulcerative colitis. Pheon Therapeutics 💸  Completed a $120m Series B financing led by TCGX, with participation from BVF Partners and other investors. The funding will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept for its first three assets in a wide range of solid tumors. SixPeaks Bio 💸  Launched with $110M funding: $30M in Series A led by Versant Ventures and $80M  non-dilutive financing from AstraZeneca. 𝐏𝐫𝐨𝐠𝐞𝐧𝐭𝐨𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 💸  Launched with $65M Series A financing led by Forbion to advance its multiple sclerosis program. Aktis Oncology 💸  Received $60M upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly to generate novel tumor-targeting radiopharmaceuticals. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Bicycle Therapeutics 🏦  Announced $555M private investment in public equity. Cytokinetics 🏦  Announced pricing of $500M stock offering. Dyne Therapeutics 🏦  Announced pricing of $325.5M public offering. Erasca, Inc.  🏦  Announced closing of $184M offering. Foghorn Therapeutics Inc. 🏦  Announced pricing of $110M direct offering and pre-funded warrants. --- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

𝐀𝐫𝐫𝐢𝐕𝐞𝐧𝐭 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐋𝐢𝐜𝐞𝐧𝐬𝐞𝐬 𝐍𝐨𝐯𝐞𝐥 𝐀𝐃𝐂 𝐟𝐫𝐨𝐦 𝐀𝐚𝐫𝐯𝐢𝐤 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 After a significant collaboration that began with a $100 million deal in December 2021, ArriVent BioPharma is now officially licensing an innovative antibody-drug conjugate (ADC) from Aarvik Therapeutics. 𝐊𝐞𝐲 𝐃𝐞𝐭𝐚𝐢𝐥𝐬: • Aarvik was responsible for the discovery and preclinical development, while ArriVent was set to take over at the human trials stage. • Though the exact upfront payment was not disclosed, Aarvik stands to gain up to $100 million, including research funding, option fees, milestone payments, and potential royalties. • The drug, based on Aarvik’s unique modular platform, is a next-generation ADC designed to advance oncology treatments. “Our advanced protein engineering technologies and ADC drug development expertise are paving the way for next-generation, best-in-class oncology therapies,” said Jagath Reddy Junutula, Ph.D., CEO and co-founder of Aarvik. ArriVent also recently 𝐫𝐚𝐢𝐬𝐞𝐝 $175 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐚𝐧 𝐈𝐏𝐎 and remains focused on bringing innovative drugs from China to Western markets, including securing rights to Allist Pharmaceuticals' EGFR tyrosine kinase inhibitor furmonertinib in 2021. Stay tuned for the updates on this collaboration. #Biotech #Oncology #ADC #DrugDevelopment #PharmaNews

Great news from Orum Therapeutics, a #Korea based #biotech has been just announced. It is filing for an initial public offering (IPO) on South Korea's #Kosdaq market. https://lnkd.in/eUW_D-_2 Company is focusing it innovation pipeline on degrader-antibody conjugates (#DACs). Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD) approach uses antibodies to deliver small molecule targeted protein degrader payloads to targeted cancer cells. The TPD technology produced two most advanced products. ORM-5029 (targets #HER2) and ORM-6151 (targets #CD33 and acquired by BMS). Great news and very interesting potential for the new therapeutic modality. South Korea's biotech industry is definitively experiencing rapid growth.

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech